Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.
Makes plasma-derived immunoglobulin therapies for immunodeficiency and infectious disease patients.
Collects plasma at its own centres, manufactures the immunoglobulin products itself, and sells them through specialty distributors, so profit depends on how much finished product each batch of plasma yields and on plasma cost. It bought its Boca Raton plasma and manufacturing assets from Biotest, a German company, in 2017.
Moat: narrow (regulatory licence, scale, installed base). FDA-licensed plasma collection and fractionation capacity is capital-intensive and slow to replicate.
Headquarters: Ramsey, New Jersey, US · Founded: 2004 · Employees: 647
Size ADMA Biologics (ADMA) is a United States Health Care company (Biotechnology) with a market value of $3.01B, the 1538th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.56 on 18 Nov 2026.
Performance Over six months the shares gained 58.4%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 6.3% over the last twelve months (peer median +18.3%); the operating margin is 44.9% (peer median -1.7%).
Valuation It trades at 16.7× forward earnings against a peer median of 29.9× (4th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +65%, so the hurdle is -65 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 27.5 points above its cost of capital (8.1% WACC).
Short interest Short interest is 8.1% of the free float (30 Oct 2026).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $519M | $510M | $426M | $258M | $154M |
| Revenue growth | — | +20% | +65% | +68% | — |
| Gross profit | $356M | $293M | $219M | $88.2M | $34.5M |
| EBITDA | $241M | $200M | $147M | $30.0M | -$32.5M |
| Net income | $182M | $147M | $198M | -$28.2M | -$65.9M |
| Free cash flow | $133M | $27.8M | $110M | $4.03M | -$73.4M |
| Capital expenditure | $8.20M | $22.9M | $8.57M | $4.98M | $13.9M |
| Total debt | $203M | $79.9M | $82.1M | $141M | $154M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| ADMA Biologics ADMA | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% |
| Grifols GRF.MC | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Kamada KMDA | $465M | +3% | +5% | 15% | 17.9× | 5.0% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ADMA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.8% | -3.3% | 3rd highest of 21 |
| 6-month return | +58.4% | -2.0% | 6th highest of 21 |
| Distance from 52-week high | -33.7% | -27.8% | 8th lowest of 21 |
| Revenue growth (TTM) | +6.3% | +18.3% | 8th lowest of 16 |
| Operating margin | 44.9% | -1.7% | highest of 17 |
| Forward P/E | 16.7× | 29.9× | 4th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -0.8% | 4.0% | 2nd least demanding of 7 |
| Growth delivered (Del g) | +64.6% | +19.9% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | -65.4 pp | -21.0 pp | least demanding of 7 |
| ROIC minus cost of capital | +27.5 pp | -8.0 pp | highest of 17 |
| EV / EBITDA | 12.8× | 53.7× | 3rd cheapest of 6 |
| Net debt / EBITDA | 0.3× | 1.1× | 2nd least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ADMA Biologics ADMA | United States | $3.01B | +58% | +6% | 45% | 16.7× | -0.8% | +64.6% |
| Telix Pharmaceuticals TLX.AX | Australia | $2.99B | -2% | +27% | -1% | 34.5× | n/a | n/a |
| Dyne Therapeutics DYN | United States | $2.97B | -10% | n/a | n/a | n/a | n/a | n/a |
| Denali Therapeutics DNLI | United States | $2.95B | -2% | n/a | -2,488% | n/a | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.94B | +68% | +37% | 21% | 66.6× | n/a | n/a |
| Xeris Biopharma XERS | United States | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% | +70.2% |
| XtalPi 2228.HK | Hong Kong | $2.87B | -34% | +4% | -127% | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% | +9.4% |
| Hualan Biological Engineering 002007.SZ | China | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% | -1.8% |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.82B | +23% | -8% | 18% | 16.6× | -4.3% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.79B | +23% | 0% | -63% | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.30B | +7% | n/a | n/a | n/a | n/a | n/a |
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.32B | -25% | -54% | -6,983% | n/a | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.72B | -7% | +20% | -3% | n/a | n/a | n/a |
| HLB 028300.KS | South Korea | $2.69B | -49% | +26% | -96% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.46B | +111% | +51% | -61% | n/a | n/a | n/a |
| Beijing Tiantan Biological Products 600161.SS | China | $3.47B | -13% | -13% | 21% | 33.1× | 2.2% | +12.5% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Disc Medicine IRON | United States | $3.55B | +16% | n/a | n/a | n/a | n/a | n/a |